Clinical trials: Neoplasms, Oral
Non-Small-Cell Lung Cancer
Oral Topotecan Versus Intravenous Docetaxel In Pretreated, Advanced Non-Small Cell Lung Cancer
The purpose of this study is to collect information on how effective and how well tolerated an oral investigational drug is compared to a standard intravenous drug in patients with pretreated, advanced non-small lung cancer…
- Trial name
- NCT00049998
- Testing
- topotecan
- Where
- 114 sites in Australia, Austria and 29 more
- Volunteers
- 760 people
- Sponsor
- GlaxoSmithKline
Diabetes Mellitus, Sarcoidosis
Salivary Proteins in Disease and Health
This study will examine saliva samples from healthy volunteers and patients with various diseases to learn more about how disease affects the mouth and salivary glands.
- Conditions
- Diabetes Mellitus, Sarcoidosis, Dental Caries, Sjorgren's Syndrome
- Trial name
- NCT00100204
- Where
- United States
- Volunteers
- 264 people, healthy volunteers welcome
- Sponsor
- National Institute of Dental and Craniofacial Research (NIDCR)
Head and Neck Cancer
S-1 or Tegafur-Uracil in Treating Patients With Previously Treated Stage III or Stage IV Head and Neck Cancer
RATIONALE: Drugs used in chemotherapy, such as S-1 and tegafur-uracil, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing.
- Trial name
- NCT00336947
- Testing
- tegafur-gimeracil-oteracil potassium, tegafur-uracil, adjuvant therapy
- Where
- 48 sites in Japan
- Volunteers
- 500 people
- Sponsor
- Yokohama City University
Oral Lichen Planus
Oral Lichen Planus and Systemical Oncological Comorbidities
Lichen planus (LP) is a chronic mucocutaneous inflammatory disease of unknown etiology. In its oral variant, oral lichen planus (OLP) has a reported prevalence ranging from 0.5% to 2.2% in the general population.
- Trial name
- NCT06449248
- Testing
- Checking of appropriateness of OLP diagnosis
- Where
- Italy
- Volunteers
- 1,517 people, healthy volunteers welcome
- Sponsor
- Catholic University of the Sacred Heart
Facial Palsy
Corticosteroids in Prevention of Facial Palsy After Cranial Base Surgery
Facial palsy after surgical removal of cranial base tumors adherent to the nerve can partly be explained by inflammation.
- Trial name
- NCT00438087
- Testing
- methylprednisolone
- Where
- France
- Volunteers
- 313 people
- Sponsor
- Assistance Publique - Hôpitaux de Paris
Chronic Pain
Effectiveness, Safety, and Tolerability Study of Oxymorphone Immediate Release (IR) Oral Liquid in Opioid Tolerant Pediatric Subjects
The purpose of this study is to evaluate the effectiveness, tolerability, and safety of oxymorphone immediate release (IR) oral liquid as an analgesic in pediatric subjects having severe to moderate chronic pain.
- Trial name
- NCT01206907
- Testing
- oxymorphone IR
- Sponsor
- Endo USA Inc., a Keenova Therapeutics Company
Osteosarcoma
A Phase II Study of Oral Cyclophosphamide and Sirolimus (OCR) in Advanced Sarcoma
The purpose of this Phase II study will assess the effectiveness of the combination of oral cyclophosphamide and sirolimus in sarcoma patients with relapsed or widespread disease who cannot be cured by surgery, radiation or…
- Trial name
- OCR (NCT00743509)
- Testing
- Cyclophosphamide and Sirolimus
- Where
- United States
- Volunteers
- 49 people
- Sponsor
- University of Michigan Rogel Cancer Center
Esophageal Squamous Cell Carcinoma, Chemoradiotherapy
To Compare the Effect of Different Nutritional Pathways on Improving Nutritional Status of Esophageal Cancer Patients Undergoing Chemoradiotherapy
This study prospectively recruited esophageal squamous-cell carcinoma patients who received nasogastric tube (NG), gastrostomy feeding and oral intake to compare the changes in nutritional status and quality of life during…
- Conditions
- Esophageal Squamous Cell Carcinoma, Chemoradiotherapy, Enteral Nutrition
- Trial name
- NCT04199832
- Testing
- Dietary guidance
- Where
- China
- Volunteers
- 156 people
- Sponsor
- Tianjin Medical University Cancer Institute and Hospital
Radiation Dermatitis Acute, Radiation Dermatitis
Oral or Topical Catechins for Radiation Dermatitis
Introduction Radiation-induced dermatitis (RID), which includes both acute and chronic forms, affects up to 95% of patients undergoing radiation therapy.
- Conditions
- Radiation Dermatitis Acute, Radiation Dermatitis, Fibrosis; Skin
- Trial name
- OCTOPUS-RD (NCT07149506)
- Testing
- Epicatechin, Epigallocatechin Gallate (EGCG), Saline (0.9% NaCl)
- Where
- Mexico
- Volunteers
- 162 people
- Sponsor
- CARLOS FRANCISCO SAAVEDRA GARCIA
Unspecified Adult Solid Tumor, Protocol Specific
3-AP in Treating Patients With Advanced or Metastatic Solid Tumors
This phase I trial is studying the side effects and best dose of 3-AP in treating patients with advanced or metastatic solid tumors. 3-AP may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth.
- Trial name
- NCT00390052
- Testing
- triapine, pharmacological study, laboratory biomarker analysis
- Where
- United States
- Volunteers
- 24 people
- Sponsor
- National Cancer Institute (NCI)
Head and Neck Cancer, Oropharyngeal Squamous Cell Carcinoma
Radiotherapy vs. Trans-Oral Surgery for HPV-Negative Oropharyngeal Squamous Cell Carcinoma
The goal of this randomized phase II study is a formal comparison of radiotherapy versus trans-oral surgery as the primary treatment of HPV-negative patients with early-stage oropharyngeal carcinoma.
- Trial name
- NCT04220749
- Testing
- Radiation, Trans-Oral Surgery (TOS) + Neck Dissection
- Where
- Canada
- Volunteers
- 68 people
- Sponsor
- London Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph's
Pain, Cancer
A Phase 2a, Proof-of-Concept Study of GIC-1001 in the Management of Visceral Pain During Sedation-Free, Full Colonoscopy
GIC-1001 is a novel, orally-administered, colonic analgesic drug developed as an alternative to i.v. sedation during full colonoscopy.
- Conditions
- Pain, Cancer, Colonic Diseases
- Trial name
- NCT01926444
- Testing
- GIC-1001
- Where
- 15 sites in United States, Canada
- Volunteers
- 308 people
- Sponsor
- gicare Pharma Inc.
Lymphoma
Bexarotene and Interferon Alfa in Treating Patients With Cutaneous T-Cell Lymphoma
RATIONALE: Drugs used in chemotherapy use different ways to stop cancer cells from dividing so they stop growing or die. Interferon alfa may interfere with the growth of cancer cells.
- Trial name
- NCT00030849
- Testing
- recombinant interferon alfa, bexarotene
- Where
- 5 sites in United States
- Sponsor
- Memorial Sloan Kettering Cancer Center
Chronic Kidney Disease, Chronic Periodontitis, Generalized, Moderate
Dental Intervention Plan for Chronic Kidney Disease Patients Awaiting or With Kidney Transplant
The study aims to understand why dental infections in end-stage kidney patients results in poor outcomes for kidney functions and eventually transplant.
- Trial name
- NCT04020458
- Testing
- dental intervention
- Where
- United States
- Volunteers
- 11 people, healthy volunteers welcome
- Sponsor
- Augusta University
Tongue Cancer
Radiotherapy of Tongue Cancer Using an Intraoral Stent
Radiotherapy of tongue cancer is associated with acute and late morbidity. Use of an intraoral stent will provide a larger distance between the tongue and palate and can reduce side-effects.
- Trial name
- NCT04337853
- Testing
- Intraoral stent, No intraoral stent
- Where
- Norway
- Volunteers
- 13 people
- Sponsor
- Oslo University Hospital
Safety Issues
Phase 1 Study of Oral RH324 in Advanced Non-Small Cell Lung Cancer
Phase 1 open label dose ranging study of RH324 in advanced non-small cell lung cancer
- Trial name
- NCT05580172
- Testing
- RH324
- Where
- United States
- Volunteers
- 6 people
- Sponsor
- ReHeva Biosciences,Inc.
Colorectal Cancer
A Study of Capecitabine (Xeloda) and Bevacizumab as a First-line Therapy in Patients With Metastatic Colorectal Cancer
This 4 arm study assessed the efficacy and safety of oral capecitabine (Xeloda) or intravenous (iv) fluorouracil/leucovorin, in combination with iv oxaliplatin (Eloxatin) with or without iv bevacizumab (Avastin), as a first-line…
- Trial name
- NCT00069095
- Testing
- Oxaliplatin 130 mg/m^2, Capecitabine 1000 mg/m^2, Bevacizumab 7.5 mg/kg
- Where
- 236 sites in United States, Australia and 31 more
- Volunteers
- 2,035 people
- Sponsor
- Hoffmann-La Roche
Advanced Solid Tumors
Safety Study to Evaluate CHR-2797 in Patients With Advanced Tumours
The primary objective of this study was to determine the safety, tolerability, dose-limiting toxicity (DLT) and maximum tolerated dose (MTD) of CHR-2797 when administered orally, once daily, to patients with advanced solid…
- Trial name
- NCT00692354
- Testing
- CHR-2797 (tosedostat)
- Volunteers
- 41 people
- Sponsor
- Chroma Therapeutics
Neoplasms
A First-In-Human Study of RO5503781 in Participants With Advanced Malignancies Except Leukemia
This multicenter, open label, dose-escalating study will evaluate the safety, pharmacokinetics, pharmacodynamics, and efficacy of RO5503781, administered once daily (QD) or once weekly (QW) in participants with advanced…
- Trial name
- NCT01462175
- Testing
- RO5503781
- Where
- 8 sites in Australia, Canada and 3 more
- Volunteers
- 99 people
- Sponsor
- Hoffmann-La Roche
Leukemia, Myeloid, Chronic, Myeloid Leukemia
Study of HQP1351 in Subjects With Refractory CML and Ph+ ALL
A multi-center, open-label, randomized, phase Ib study to evaluate the pharmacokinetics (PK) of HQP1351 and to determine the recommended phase 2 dose (RP2D) of HQP1351 in subjects with CML chronic phase (CP), accelerated phase…
- Conditions
- Leukemia, Myeloid, Chronic, Myeloid Leukemia, Chronic Myeloid Leukemia, Philadelphia Positive Acute Lymphoblastic Leukemia
- Trial name
- NCT04260022
- Testing
- Ascentage Pharma HQP1351 bioavailable inhibitor, Blinatumomab
- Where
- 9 sites in United States, Canada
- Volunteers
- 242 people
- Sponsor
- Ascentage Pharma Group Inc.
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.